Vincerx Pharma's Preclinical Data From Blood Cancer Candidate Shows Efficacy, Lower Toxicity

Vincerx Pharma Inc VINC presented a poster of VIP924 preclinical data at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
High expression of CXCR5 was observed by immunohistochemistry on naive and previously treated diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL) samples; with limited expression in healthy tissues.
VIP924 showed superior in vitro cytotoxicity across different non-Hodgkin lymphoma cell lines compared with other B-cell lymphoma targeting antibodies conjugated to the same effector chemistry.
VIP924 (10mg/kg) resulted in significant tumor growth inhibition in two DLBCL patient-derived tumor models: 68% in a low CXCR5-expressing model and 87% in a high CXCR5-expressing model.
Prolonged survival of VIP924-treated animals was observed in both models. No effect on body weight or adverse effects in the VIP924-treated mice were observed.
To determine the efficacy of VIP924 in large, established tumors, a single VIP924 dose of 10mg/kg was administered in mice transplanted with the HBL-1 lymphoma cell line.
Complete responses were observed in 2 out of 3 mice with no measurable tumors on treatment day 26.
After 24 and 48 hours, accumulation of VIP716 (ie, payload; "metabolite") was observed in the tumors but not in plasma.
Price Action: VINC shares are down 4.21% at $0.98 on the last check Wednesday.